MXPA04009236A - Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. - Google Patents
Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.Info
- Publication number
- MXPA04009236A MXPA04009236A MXPA04009236A MXPA04009236A MXPA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A
- Authority
- MX
- Mexico
- Prior art keywords
- comorbidites
- diabetes
- pioglitazone
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion esta relacionada con la industria farmaceutica en general y con la industria de la manufactura de productos farmaceuticos para el tratamiento de diabetes y sus comorbilidades. Las ventajas de la presente invencion con respecto de las composiciones del estado de la tecnica radica en que el presente hace posible un manejo a largo plazo de un cuadro diabetico para mantener un control glucemico adecuado; logrando un efecto mas potente sobre la hiperglucemia permitiendo reducir las dosis y por lo tanto los efectos colaterales individuales de las drogas; mejora la sensibilidad a la insulina de los receptores beta pancreaticos corrigiendo simultaneamente los trastornos de secrecion de insulina y favorece el metabolismo lipidico, mejorando asimismo el perfil del mismo en el plasma sanguineo. La composicion esta formada por un agente hipoglucemiante y un agente antihiperglucemiante. Siendo glimepirida el primero y pioglitazona el segundo. La pioglitazona se encuentra en la composicion en una cantidad entre 5 y 2500 mg y la glimepirida entre 1 y 250 mg.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04009236A MXPA04009236A (es) | 2004-09-23 | 2004-09-23 | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
PCT/MX2005/000057 WO2006033568A1 (es) | 2004-09-23 | 2005-07-18 | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04009236A MXPA04009236A (es) | 2004-09-23 | 2004-09-23 | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04009236A true MXPA04009236A (es) | 2006-03-27 |
Family
ID=36090288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04009236A MXPA04009236A (es) | 2004-09-23 | 2004-09-23 | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
Country Status (2)
Country | Link |
---|---|
MX (1) | MXPA04009236A (es) |
WO (1) | WO2006033568A1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
-
2004
- 2004-09-23 MX MXPA04009236A patent/MXPA04009236A/es active IP Right Grant
-
2005
- 2005-07-18 WO PCT/MX2005/000057 patent/WO2006033568A1/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006033568A1 (es) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
MX2009012000A (es) | Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis. | |
WO2006120574A3 (en) | Analogs of 4-hydroxyisoleucine and uses thereof | |
MXPA05009933A (es) | Composiciones que comprenden acidos grasos y aminoacidos. | |
TW200738246A (en) | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | |
MX2009003305A (es) | Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso. | |
IL213425A0 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase | |
RS20050532A (en) | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | |
MX347145B (es) | Derivados de adamantilo-acetamida como inhibidores de la enzima tipo i de 11-beta-hidroxiesteroide deshidrogenasa. | |
BR0314996A (pt) | Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada | |
WO2008124505A3 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
WO2018169282A3 (ko) | Atpif1을 함유하는 당뇨 치료용 약학조성물 | |
TN2009000095A1 (en) | Thiazole pyrazolopyrimidines as crf1 receptor antagonists | |
WO2007123511A3 (en) | Dosing regimens for the treatment of cancer | |
CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
WO2008071790A3 (en) | Novel compositions and uses thereof | |
UA86441C2 (ru) | (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе | |
MX2007009985A (es) | Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos. | |
MXPA04009236A (es) | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. | |
MX337606B (es) | Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal. | |
NO20050398L (no) | Nye adenosinanaloger og deres anvendelse som farmasoytiske midler | |
TNSN06072A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
UA94975C2 (ru) | Композиция и ее применение для лечения гипергликемии и связанных с ней болезней | |
IL185805A0 (en) | Substituted, bicyclic 8-pyrrolidino-benzimidazoles, method for their production and their use as medicaments | |
DK1778359T3 (da) | Farmaceutiske sammensætninger til lindring af oxcessive sukkerniveauer hos patienter med diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or assignment | ||
GD | Licence granted |